Clinical trials in spontaneous disease in dogs: A new paradigm for investigations of sepsis: State-of-the-Art Review

Journal of Veterinary Emergency and Critical Care

Volumn 17, Issue 4, 2007, Pages 359-367

  Otto, Cynthia M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clinical trials; Dogs; Parvovirus; Peritonitis; Pneumonia; SIRS; Translational research

Indexed keywords

ANIMALIA; CANINE PARVOVIRUS; CANIS FAMILIARIS; PARVOVIRUS;

EID: 36448980678     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2007.00249.x     Document Type: Review

References (116)

1. Anonymous. American college of chest physicians/society of critical care medicine consensus conference: definitions for sepsis,organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 20 (6) : 864 874.
2. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 348 (16) : 1546 1554.
3. CDC. Statistics NCfH, Health, United States, 2005, Chartbook on Trends in the Health of Americans. Hyattsville, MD : CDC 2005
4. Hinshaw LB. High-dose corticosteroids in the critically ill patient. Current concept and future developments. Acta Chir Scand 1985 526 (Suppl.) : 129 137.
5. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit Care Med 2004 32 (11 Suppl.) : S527 S533.
6. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995 23 (8) : 1430 1439.
7. Anonymous. The french national registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The national committee for the evaluation of centoxin. Arch Intern Med 1994 154 (21) : 2484 2491.
8. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 sepsis study group. Crit Care Med 1995 23 (6) : 994 1006.
9. Greenman RL, Schein RM, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA sepsis study group. JAMA 1991 266 (8) : 1097 1102.
10. McCloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS trial study group. Ann Intern Med 1994 121 (1) : 1 5.
11. Ziegler EJ, Fisher CJ Jr., Sprung CL, et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A sepsis study group. N Engl J Med 1991 324 (7) : 429 436.
12. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982 307 (20) : 1225 1230.
13. Calandra T, Glauser MP, Schellekens J, et al. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 1988 158 (2) : 312 319.
14. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998 351 (9107) : 929 933.
15. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis study group. JAMA 1995 273 (12) : 934 941.
16. Cohen J, Carlet J. Intersept: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International sepsis trial study group. Crit Care Med 1996 24 (9) : 1431 1440.
17. Fisher CJ Jr., Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 sepsis syndrome study group. Crit Care Med 1993 21 (3) : 318 327.
18. Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Crit Care Med 2001 29 (4) : 765 769.
19. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996 24 (5) : 733 742.
20. Abraham E, Glauser MP, Butler T, et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 study group. JAMA 1997 277 (19) : 1531 1538.
21. Fisher CJ Jr., Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group. N Engl J Med 1996 334 (26) : 1697 1702.
22. Fisher CJ, Dhainaut JA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994 271 : 1836 1843.
23. Opal SM, Fisher CJ Jr., Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med 1997 25 (7) : 1115 1124.
24. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985 229 (4716) : 869 871.
25. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987 330 (6149) : 662 664.
26. Dunn D, Priest B, Condie R. Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch Surg 1988 123 (11) : 1389 1393.
27. Spapen HD, Diltoer M, Huyghens LP. Passive immunotherapy of Gram-negative bacteremia, sepsis and septic shock. Acta Clin Belg 1993 48 (1) : 20 29.
28. Marshall JC. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Dis 2003 2 (5) : 391 405.
29. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999 25 (6) : 556 566.
30. Vincent JL, Laterre PF, Cohen J, et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005 23 (5) : 400 405.
31. Dhainaut JF, Tenaillon A, Hemmer M, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 sepsis investigator group. Crit Care Med 1998 26 (12) : 1963 1971.
32. Opal S, Laterre PF, Abraham E, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004 32 (2) : 332 341.
33. Vincent JL, Spapen H, Bakker J, et al. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 2000 28 (3) : 638 642.
34. Watson D, Grover R, Anzueto A, et al. Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004 32 (1) : 13 20.
35. Fein AM, Bernard GR, Criner GJ, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and sepsis study group. JAMA 1997 277 (6) : 482 487.
36. Arons MM, Wheeler AP, Bernard GR, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in sepsis study group. Crit Care Med 1999 27 (4) : 699 707.
37. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N Engl J Med 1997 336 (13) : 912 918.
38. Anonymous. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The veterans administration systemic sepsis cooperative study group. N Engl J Med 1987 317 (11) : 659 665.
39. Bone RC, Fisher CJ Jr., Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987 317 (11) : 653 658.
40. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections: a double-blind study. N Engl J Med 1971 284 (22) : 1248 1250.
41. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984 311 (18) : 1137 1143.
42. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988 138 (1) : 62 68.
43. Root RK, Lodato RF, Patrick W, et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003 31 (2) : 367 373.
44. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001 286 (15) : 1869 1878.
45. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001 29 (11) : 2081 2089.
46. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock 1998 9 (1) : 1 11.
47. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Disc 2005 4 (10) : 854 865.
48. Marshall JC, Deitch E, Moldawer LL, et al. Preclinical models of shock and sepsis: what can they tell us? Shock 2005 24 (Suppl. 1) : 1 6.
49. Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007 81 (1) : 137 143.
50. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997 112 : 235 243.
51. Osuchowski MF, Welch K, Siddiqui J, et al. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006 177 (3) : 1967 1974.
52. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003 29 (4) : 530 538.
53. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004 32 (11) : 2173 2182.
54. Remick DG, Bolgos GR, Siddiqui J, et al. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002 17 (6) : 463 467.
55. Remick DG, Ward PA. Evaluation of endotoxin models for the study of sepsis. Shock 2005 24 (Suppl. 1) : 7 11.
56. Taveira da Silva AM, Kaulbach HC, Chuidian FS, et al. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993 328 (20) : 1457 1460.
57. Nguyen HB, Rivers EP, Abrahamian FM, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med 2006 48 (1) : 28 54.
58. de Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 2003 17 (5) : 674 679.
59. Hubbard WJ, Choudhry M, Schwacha MG, et al. Cecal ligation and puncture. Shock 2005 24 (Suppl. 1) : 52 57.
60. Deitch EA. Rodent models of intra-abdominal infection. Shock 2005 24 (Suppl. 1) : 19 23.
61. Goldfarb RD, Dellinger RP, Parrillo JE. Porcine models of severe sepsis: emphasis on porcine peritonitis. Shock 2005 24 (Suppl. 1) : 75 81.
62. Hollenberg SM. Mouse models of resuscitated shock. Shock 2005 24 (Suppl. 1) : 58 63.
63. Redl H, Bahrami S. Large animal models: baboons for trauma, shock and sepsis studies. Shock 2005 24 (Suppl. 1) : 88 93.
64. Taft RA, Davisson M, Wiles MV. Know thy mouse. Trends Genet 2006 22 (12) : 649 653.
65. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005 365 (9453) : 63 78.
66. Oberholzer A, Keel M, Zellweger R, et al. Incidence of septic complications and multiple organ failure in severely injured patients is sex specific. J Trauma 2000 48 (5) : 932 937.
67. Krabbe KSr, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol 2004 39 (5) : 687 699.
68. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 (10) : 699 709.
69. Ganopolsky JG, Castellino FJ. A protein C deficiency exacerbates inflammatory, hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 2004 165 (4) : 1433 1446.
70. Hazelzet JA. How to enhance our knowledge of activated protein C during pediatric sepsis trials: pediatric versus adult trials. Pediatr Crit Care Med 2006 7 (3) : 277 278.
71. Redl H, Bahrami S, Schlag G, et al. Clinical detection of LPS and animal models of endotoxemia. Immunobiology 1993 187 (3-5) : 330 345.
72. Natanson C, Fink MP, Ballantyne HK, et al. Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 1986 78 (1) : 259 270.
73. Natanson C, Danner RL, Reilly JM, et al. Antibiotics versus cardiovascular support in a canine model of human septic shock. Am J Physiol 1990 259 (5 Part 2) : H1440 H1447.
74. Parent C, King LG, Walker LM, et al. Clinical and clinicopathologic findings in dogs with acute respiratory distress syndrome: 19 cases (1985-1993). J Am Vet Med Assoc 1996 208 (9) : 1419 1427.
75. King LG. Postoperative complications, prognostic indicators in dogs and cats with septic peritonitis: 23 cases (1989-1992). J Am Vet Med Assoc 1994 204 (3) : 407 414.
76. Turk J, Miller M, Brown T, et al. Coliform septicemia and pulmonary disease associated with canine parvoviral enteritis: 88 cases (1987-1988). J Am Vet Med Assoc 1990 196 (5) : 771 773.
77. Coughlin PA, Mavor AI. Arterial consequences of recreational drug use. Eur J Vasc Endovasc Surg 2006 32 (4) : 389 396.
78. O'Brien JM Jr., Lu B, Ali NA, et al. Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med 2007 35 (2) : 345 350.
79. Mack GS. Cancer researchers usher in dog days of medicine. Nat Med 2005 11 (10) : 1018.
80. Waters DJ, Wildasin K. Cancer clues from pet dogs. Sci Am 2006 295 (6) : 94 101.
81. Isogai E, Isogai H, Onuma M, et al. Escherichia coli associated endotoxemia in dogs with parvovirus infection. Nippon Juigaku Zasshi 1989 51 (3) : 597 606.
82. Turk J, Fales W, Miller M, et al. Enteric Clostridium perfringens infection associated with parvoviral enteritis in dogs: 74 cases (1987-1990). J Am Vet Med Assoc 1992 200 (7) : 991 994.
83. Pollock RV, Coyne MJ. Canine parvovirus. Vet Clin North Am Small Anim Pract 1993 23 (3) : 555 568.
84. Prittie J. Canine parvoviral enteritis: a review of diagnosis, management and prevention. J Vet Emerg Crit Care 2004 14 (3) : 167 176.
85. Krakowka S, Olsen RG, Axhelm MS, et al. Canine parvovirus infection potentiates canine distemper encephalitis attributable to modified live-virus vaccine. J Am Vet Med Assoc 1982 180 (2) : 137 139.
86. Dimmitt R. Clinical experience with cross-protective anti-endotoxin antiserum in dogs with parvoviral enteritis. Canine Pract 1991 16 (3) : 23 26.
87. Rewerts JM, McCaw DL, Cohn LA, et al. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection. J Am Vet Med Assoc 1998 213 (7) : 991 992.
88. Otto CM, Jackson CB, Rogell E, et al. Recombinant bactericidal/ permeability increasing protein (rBPI21) for treatment of parvovirus enteritis: a randomized, double-blinded, placebo-controlled clinical trial. J Vet Intern Med 2001 15 : 355 360.
89. Mohr AJ, Leisewitz AL, Jacobson LS, et al. Effect of early enteral nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with severe parvoviral enteritis. J Vet Intern Med 2003 17 (6) : 791 798.
90. de Mari K, Maynard L, Eun HM, et al. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Vet Rec 2003 152 (4) : 105 108.
91. Martin V, Najbar W, Gueguen S, et al. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet Microbiol 2002 89 (2-3) : 115 127.
92. Creasey AA, Stevens P, Kenney J, et al. Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock 1991 33 (2) : 84 91.
93. de Groote MA, Martin MA, Densen P, et al. Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs. placebo. J Am Med Assoc 1989 262 (2) : 249 251.
94. Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 immunoglobulin study group. J Infect Dis 1990 161 (5) : 982 987.
95. Tracey KJ, Cerami A. Tumor necrosis factor: an updated review of its biology. Crit Care Med 1993 21 (10) : S415 S422.
96. Glickman LT, Domanski LM, Patronek GJ, et al. Breed-related risk factors for canine parvovirus enteritis. J Am Vet Med Assoc 1985 187 (6) : 589 594.
97. Mantione NL, Otto CM. Characterization of the use of antiemetic agents in dogs with parvoviral enteritis treated at a veterinary teaching hospital: 77 cases (1997-2000). J Am Vet Med Assoc 2005 227 (11) : 1787 1793.
98. Nemzek JA, Agrodnia MD, Hauptman JG. Breed-specific pro-inflammatory cytokine production as a predisposing factor for susceptibility to sepsis in the dog. J Vet Emerg Crit Care 2007 : 368 372.
99. Hauptman JG, Walshaw R, Olivier NB. Evaluation of the sensitivity and specificity of diagnostic criteria for sepsis in dogs. Vet Surg 1997 26 : 393 397.
100. Okano S, Tagawa M, Takase K. Relationship of the blood endotoxin concentration and prognosis in dogs with pyometra. J Vet Med Sci 1998 60 (11) : 1265 1267.
101. Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995 273 (2) : 117 123.
102. Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability and fibrinolysis. J Vet Emerg Crit Care 2005 15 (1) : 9 16.
103. Otto C, Rieser T, Brooks M, et al. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000 217 (10) : 1500 1504.
104. Mann FA, Boon GD, Wagner-Mann CC, et al. Ionized and total magnesium concentrations in blood from dogs with naturally acquired parvoviral enteritis. J Am Vet Med Assoc 1998 212 (9) : 1398 1401.
105. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001 345 (19) : 1368 1377.
106. Otto CM, Drobatz K, Soter C. Endotoxemia and tumor necrosis factor in clinical canine parvoviral enteritis. J Vet Int Med 1997 11 (2) : 65 70.
107. Cohn LA, Rewerts JM, McCaw D, et al. Plasma granulocyte colony-stimulating factor concentrations in neutropenic, parvoviral enteritis-infected puppies. J Vet Intern Med 1999 13 (6) : 581 586.
108. Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 meningococcal sepsis study group. Lancet 2000 356 (9234) : 961 967.
109. Greenfield C, Walshaw R. Open peritoneal drainage for treatment of contaminated peritoneal cavity, septic peritonitis in dogs and cats: 24 cases (1980-1986). J Am Vet Med Assoc 1987 191 (1) : 100 105.
110. Lanz OI, Ellison GW, Bellah JR, et al. Surgical treatment of septic peritonitis without abdominal drainage in 28 dogs. J Am Anim Hosp Assoc 2001 37 (1) : 87 92.
111. Mueller MG, Ludwig LL, Barton LJ. Use of closed-suction drains to treat generalized peritonitis in dogs and cats: 40 cases (1997-1999). J Am Vet Med Assoc 2001 219 (6) : 789 794.
112. Staatz AJ, Monnet E, Seim HB III. Open peritoneal drainage versus primary closure for the treatment of septic peritonitis in dogs and cats: 42 cases (1993-1999). Vet Surg 2002 31 (2) : 174 180.
113. Bonczynski JJ, Ludwig LL, Barton LJ, et al. Comparison of peritoneal fluid and peripheral blood pH, bicarbonate, glucose, and lactate concentration as a diagnostic tool for septic peritonitis in dogs and cats. Vet Surg 2003 32 (2) : 161 166.
114. Radhakrishnan A, Drobatz KJ, Culp WT, et al. Community-acquired infectious pneumonia in puppies: 65 cases (1993-2002). J Am Vet Med Assoc 2007 230 (10) : 1493 1497.
115. Jameson PH, King LA, Lappin MR, et al. Comparison of clinical signs, diagnostic findings, organisms isolated and clinical outcome in dogs with bacterial pneumonia: 93 cases (1986-1991). J Am Vet Med Assoc 1995 206 (2) : 206 209.
116. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000 342 (18) : 1334 1349.